Lv4
464 积分 2026-07-18 加入
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates
30天前
已完结
Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices
30天前
已完结
Route Design and Scale-Up of a Topoisomerase I Inhibitor Antibody–Drug Conjugate Payload
30天前
已完结
Impurity qualification requirements for drug-linkers related impurities used to generate antibody-drug conjugates
30天前
已完结
Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)
30天前
已完结
Purge Factor Analysis and Proposal for Non-conjugatable Impurity Clearance in Post-conjugation Purification of ADCs
30天前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
30天前
已完结
Process Development for the First GMP Synthesis of SGD-9501-TFA, Part 1: Synthesis of Two Oligopeptide Fragments
1个月前
已完结
Use of Impinging Jet to Improve Scalability in the Preparation of the ABBV-154 Drug-Linker
1个月前
已完结
Development and Execution of a Scalable Route to an Immunology ADC Drug-Linker for ABBV-154
1个月前
已完结
皖公网安备34019202002308
